Hemosol Inc.

An integrated biopharmaceutical company developing a multi-product pipeline for global markets based on proprietary technologies, used initially in the treatment of hemoglobin deficiencies. As a near-term commercial stage company, our immediate focus is the development and successful commercialization of HemolinkT, a hemoglobin replacement product (historically termed a blood substitute). Our Goal To become a profitable, biopharmaceutical company with an international reputation for integrity and innovation with products that promote the well-being of patients who suffer from hemoglobin deficiency.

Previous Forums
Date/Time		Forum
Jun 25 2001		BIO 2001 San Diego International Convention - Day 1 of 3

Market Assistant		PrecisionAlert
Earnings Data Annual Report		Enter your email address to receive alerts about this company